Accessibility Menu
Ascendis Pharma A/s logo

Ascendis Pharma A/s(NASDAQ) ASND

Market Cap$15.86BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)+4%
5 Year+106%
1 Year+34%
1 Month-8%
$255.91
+2.43%
+6.06Today
After hours$255.48-$0.43 (-0.17%)
Ascendis Pharma A/s last closing stock price
MetricPriceDate
Last closeUSD 255.412026-08-07
Ascendis Pharma A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.71%USD 243.912026-07-31
1 month-7.85%USD 277.182026-07-08
3 month+7.02%USD 238.662026-05-08
Year to date+19.78%USD 213.242025-12-31
1 year+34.18%USD 190.352025-08-07
3 year+171.45%USD 94.092023-08-08
5 year+106.43%USD 123.732021-08-06
Since inception+4.09%USD 245.382026-04-20

Ascendis Pharma A/s Financials at a Glance

Market Cap

$15.86BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€867.51M

Net Income (TTM)

€506.60M

EPS (TTM)

$8.87

P/E Ratio

27.18

Dividend

$0.00

Beta (Volatility)

0.74 (Low)

Price

$255.91

Volume

325,562.087

Open

$251.76

Previous Close

$255.41

Daily Range

$251.76 - $257.57

52-Week Range

$186.05 - $282.15

Estimated Earnings Date

Aug 6, 2026

ASND News

SellAlert-Blue.png

What to Know About This Fund’s $50 Million Exit From Ascendis Pharma

Jonathan PoncianoMay 14, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ascendis Pharma A/s

Ascendis Pharma A/S is a biopharmaceutical company focused on developing innovative therapeutic solutions for critical medical conditions. The company is known for its flagship product, SKYTROFA, which addresses growth hormone deficiency (GHD) and has a promising pipeline of TransCon-branded candidates.

Products and Services
  • SKYTROFA for growth hormone deficiency treatment
  • TransCon Growth Hormone for pediatric and adult GHD
  • TransCon parathyroid hormone for hypoparathyroidism
Growth Outlook
  • Strong pipeline with multiple candidates in various stages of development
  • Expansion into new markets, including Japan for pediatric GHD
  • Potential for significant revenue growth as products gain market approval
Financial Highlights
  • Recent quarterly revenue of 250.66 million EUR, showing strong demand
  • Trailing twelve months (TTM) revenue of 1.01 billion EUR, indicating growth
  • Gross profit margin of 91.37% in the latest quarter, reflecting operational efficiency
Ascendis Pharma A/S is positioned to capitalize on unmet medical needs through its innovative therapies. The company’s focus on growth hormone deficiencies and related conditions highlights its commitment to addressing significant health challenges. With a robust pipeline and recent financial performance indicating strong demand, Ascendis Pharma presents an intriguing opportunity for potential investors interested in the biotechnology sector. The company's strategic expansion into new markets and ongoing development of its product offerings further enhance its growth potential.
AI Generated • Jul 21, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Jan Møller Mikkelsen

Website

www.ascendispharma.com

Headquarters

Hellerup, CR 2900, DK

ASND Financials

Key Financial Metrics (TTM)

Gross Margin

88.17%

Operating Margin

-0.80%

Net Income Margin

58.40%

Return on Equity

-5641.90%

Return on Capital

-18.47%

Return on Assets

25.26%

Earnings Yield

3.68%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$15.86BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

62.11M

Volume

325.56K

Avg. Volume

673.70K

Financials (TTM)

Gross Profit

€764.89M

Operating Income

-€6.93M

EBITDA

€12.37M

Operating Cash Flow

€57.63M

Capital Expenditure

-€15.53M

Free Cash Flow

€42.11M

Cash & ST Invst.

€573.42M

Total Debt

€897.60M

Ascendis Pharma A/s Performance Analysis

Ascendis Pharma A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 53,782,560485.0%
20232023-12-31EUR 288,352,991436.1%
20242024-12-31EUR 393,347,10836.4%
20252025-12-31EUR 812,725,097106.6%
Ascendis Pharma A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3056.6%
Q32025-09-3035.2%
Q42025-12-3114.8%
Q12026-03-312.2%
Ascendis Pharma A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -10.9332.1%
20232023-12-31EUR -9.25-15.4%
20242024-12-31EUR -7.06-23.6%
20252025-12-31EUR -4.25-39.9%
Ascendis Pharma A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3048.1%
Q32025-09-30-22.0%
Q42025-12-3146.0%
Q12026-03-311935.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

€250.66M

+148.3%

Gross Profit

€229.03M

+174.5%

Gross Margin

91.37%

N/A

Market Cap

$15.86BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$13.34M

N/A

Employees

1,189

N/A

Net Income

€639.69M

+776.0%

EBITDA

€23.68M

+153.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

€573.42M

+10.7%

Total Debt

€897.60M

+5.9%

Accounts Receivable

€196.81M

+195.1%

Inventory

€314.67M

+7.4%

Long Term Debt

€386.51M

+8.2%

Short Term Debt

€511.09M

+4.3%

Return on Assets

25.26%

N/A

Return on Invested Capital

-0.79%

N/A

Free Cash Flow

-€15.69M

-4.5%

Operating Cash Flow

-€7.85M

+45.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BBIOBridgeBio Pharma, Inc.
$84.48+2.03%
EXELExelixis, Inc.
$54.07+3.58%
BMRNBioMarin Pharmaceutical Inc.
$63.81+3.82%
MDGLMadrigal Pharmaceuticals, Inc.
$510.04-0.06%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$133.11+0.16%
TTDThe Trade Desk
$13.80-0.22%
NVDANvidia
$223.96+0.02%
TLTiShares Trust - iShares 20+ Year Treasury Bond ETF
$82.76+0.00%

Questions About ASND

What is the current price of Ascendis Pharma A/s?

Ascendis Pharma A/s is trading at $255.41 per share.

What is the 52-week range for Ascendis Pharma A/s?

Over the past 52 weeks, Ascendis Pharma A/s has traded between $186.05 and $282.15.

How much debt does Ascendis Pharma A/s have?

As of the most recent reporting period, Ascendis Pharma A/s reported total debt of €1.03B.

How much cash does Ascendis Pharma A/s have on hand?

Ascendis Pharma A/s reported €660.00M in cash and cash equivalents in its most recent financial results.

What is Ascendis Pharma A/s’s dividend yield?

Ascendis Pharma A/s does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services